Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
PARA Paramount Global
TFINP Triumph Financial Inc
HWKN Hawkins Inc
COUP Coupa Software Inc
ACAZF Acadian Timber Corp
BSX Boston Scientific Corp
ACDVF Air Canada
DCFCW Tritium DCFC Equity Warrant Exp 13th Jan 2027 *W EXP 01/13/2027
CBWTF Auxly Cannabis Group Inc

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. is a research-based biopharmaceutical company, which is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta; aesthetics products that include Botox Cosmetic, Juvederm Collection and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products consists of Lumigan, Alphagan and Restasis; women's health products include Lo Loestrin, Orilissa and others; and other products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. Its products are sold to wholesalers, government agencies, health care facilities and independent retailers. It also discovers and develop antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).


Last Trade
0.26 (0.18%)
B/A Size

Market Hours

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:



6 providers
January 25, 2023
Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'. This is a customer centric approach, which supports...(PR Newswire)

January 18, 2023

With JUVÉDERM(R) VOLUX™ XC, You Can Receive Non-Surgical Jawline Augmentation in Your Aesthetic Provider's Office Today, Allergan Aesthetics, an AbbVie company (NYSE:ABBV), announced the highly anticipated national launch of JUVÉDERM(R)VOLUX™ XC...(PR Newswire)

January 17, 2023
SkinMedica(R) Launches Even & Correct

The Results Are Clear - A Scientifically Proven Path to Targeting the Appearance of Hyperpigmentation and Improving Skin Tone and Texture Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of the long-awaited...(PR Newswire)

January 16, 2023
January 10, 2023
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets

Collaboration leverages Anima's mRNA Lightning technology platform and AbbVie's extensive expertise in Oncology and Immunology- Anima will receive an upfront payment of $42 million with potential for further milestones and royalties (PR Newswire)

January 06, 2023
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets

Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery Engine- Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development...(PR Newswire)

AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets

--- Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered royalties AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a...(BusinessWire)

January 05, 2023
AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its fourth-quarter 2022 financial results on Thursday, February 9, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's...(PR Newswire)

January 03, 2023
AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023. Richard A. Gonzalez, chairman and chief executive officer, will present at 5:00 p.m. CT. (PR Newswire)

December 16, 2022
U.S. FDA Approves VRAYLAR(R) (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder

Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant therapy (ADT), showing improvement in symptoms when...(PR Newswire)

AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS(R) (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age

-- If approved, linaclotide would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age 1 -- Submission is based on positive Phase 3 study data demonstrating linaclotide (72mcg) resulted in...(PR Newswire)

December 15, 2022
AbCellera and AbbVie Partner to Advance New Antibody Therapies

AbCellera (Nasdaq: ABCL) announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. (NYSE: ABBV). The partnership will leverage AbCellera's antibody discovery and development engine to deliver...(BusinessWire)

December 12, 2022
AbbVie Named to Dow Jones Sustainability World Index for 10th Straight Year

-- AbbVie Ranked #1 in Biotech Sector on the 2022 S&P Corporate Sustainability Assessment AbbVie (NYSE: ABBV) today announced that for the tenth consecutive year, it has been named to the Dow Jones Sustainability World Index (DJSI World) and Dow...(PR Newswire)

December 11, 2022
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody(R)-CD3xCD20) Across B-Cell Lymphomas

-- Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) follicular lymphoma, previously untreated follicular lymphoma, R/R diffuse large B-cell lymphoma and...(PR Newswire)

December 10, 2022
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients

-- Exploratory analysis from Cohort 3 of the Phase 2 REFINE study presented in an oral session at ASH AbbVie (NYSE: ABBV) today announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with...(PR Newswire)

December 06, 2022
AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline

-- Collaboration leverages HotSpot's Smart Allostery™drug discovery platform for the development of the first and only small molecule IRF5 (interferon regulatory factor 5) inhibitor for the potential treatment of autoimmune diseases (PR Newswire)

AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress

Fifteen abstracts underscore AbbVie's commitment to people living with migraine -- AbbVie to present late-breaking data from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) study on neck pain with headache in people with and...(PR Newswire)

December 01, 2022
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies News Commentary - Pancreatic cancer accounts for over 3% of all types of cancers in US. A lethal type of cancer, pancreatic cancer starts in the pancreas of the human body when abnormal cells in the pancreas grow and divide...(PR Newswire)

November 23, 2022
AbbVie to Present at the Evercore ISI HealthCONx Conference

AbbVie (NYSE: ABBV) will participate in the 5th Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, November 29, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott...(PR Newswire)

AbbVie Announces European Commission Approval of SKYRIZI(R) (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease

Third approved indication for SKYRIZI(R)(risankizumab) and the first specific IL-23 inhibitor for the treatment of Crohn's disease in the European Union (EU) - A significantly higher proportion of patients on SKYRIZI achieved clinical remission...(PR Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.